Letters to the Editor

Olmesartan for the Prevention or Delay of Diabetic Nephropathy: Some Considerations

Uso de olmesartán en la prevención o retraso de la nefropatía diabética: algunas consideraciones

To the Editor,

We read with great interest the scientific letter recently published in your journal by Consuegra-Sánchez et al. entitled “Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?”1 The authors presented a meta-analysis of randomized clinical trials with placebo controls analyzing the combined effects of angiotensin-II receptor blockers (ARBs) on mortality in patients with type 2 diabetes mellitus. Without a doubt, this is an interesting study that showed the absence of all-cause risk of mortality in the diabetic population being treated with ARBs, but we would like to make a few clarifications regarding the results presented.

First, the title used poses a direct question regarding olmesartan, which invites reflection on the part of the reader; above all following the publication of the results from the Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.2 However, the combination of the results from the 5 trials analyzed, which covered 4 different drugs (irbesartan, candesartan, losartan, and olmesartan) is insufficient to respond to such a question.

The metaanalysis does not consider the effect of olmesartan (or any other ARBs) in cardiovascular mortality since it only refers to information regarding overall mortality rates, as explained by the authors. However, the authors briefly discuss the results observed in the ROADMAP study,2 which reported an increase in cardiovascular mortality (one of the primary variables evaluated) in diabetic patients treated with olmesartan.

Due to the major clinical relevance of cardiovascular mortality in this population, we performed a complementary search of the clinicaltrials.gov database using the keyword “olmesartan.” The 85 results (accessed on 5 March 2012) included 2 additional completed randomized clinical trials (studies NCT00362960 and NCT00141453: Olmesartan Reducing Incidence of Endstage renal disease in diabetic Nephropathy Trial [ORIENT]).3,4 They evaluated the effects of olmesartan on diabetic patients with or without proteinuria, renal disease, and/or cardiovascular disease. Only one of these was already published (ORIENT).3 The pooled data from the two studies (ROADMAP and ORIENT) allowed us to observe an increased cardiovascular mortality associated with olmesartan (25 cases; 1%) compared to the placebo (6 cases; 0.2%) (odds ratio: 3.6; 95% confidence interval: 1.5-9.1; Figure). It is particularly important that the risk of cardiovascular death in the ROADMAP study was 10 times higher in diabetic patients treated with olmesartan who had a history of coronary disease (Figure). In light of these data, and as a response to the question posed by Consuegra-Sánchez et al., the results from the two studies are not very promising. We must point out that approximately 49% (n=2163) of diabetic patients in the

<table>
<thead>
<tr>
<th>Study</th>
<th>Olmesartan Cases/population</th>
<th>Placebo Cases/population</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROADMAP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetic population with coronary disease</td>
<td>11/564</td>
<td>1/540</td>
<td>10.7 (1.4-83.3)</td>
</tr>
<tr>
<td>Diabetic population without coronary disease</td>
<td>4/1668</td>
<td>2/1675</td>
<td>2.0 (0.4-10.9)</td>
</tr>
<tr>
<td>Subtotal</td>
<td>15/2232</td>
<td>3/2215</td>
<td>4.0 (1.1-14.7)</td>
</tr>
<tr>
<td>ORIENT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetic population</td>
<td>10/282</td>
<td>3/284</td>
<td>3.4 (0.9-12.1)</td>
</tr>
<tr>
<td>Subtotal</td>
<td>10/282</td>
<td>3/284</td>
<td>3.4 (0.9-12.1)</td>
</tr>
<tr>
<td>TOTAL (in the diabetic population)</td>
<td>25/2514</td>
<td>6/2499</td>
<td>3.6 (1.5-9.1)</td>
</tr>
</tbody>
</table>

Heterogeneity: I²=0.0%; P=.046

In favor of olmesartan In favor of placebo

Figure. Cardiovascular mortality associated with olmesartan: ROADMAP and ORIENT. In order to combine the study results, we used a fixed effects inverse variance model. We did not observe significant differences between the two studies (I²=0.0%); 95% CI, 95% confidence interval; OR, odds ratio.
ROADMAP study had normal blood pressure and/or controlled hypertension (with at least one other cardiovascular risk factor) at the start of the study. Finally, we would like to mention that in Spain, olmesartan is authorized exclusively for the treatment of arterial hypertension.\(^5\)

**Note**

The opinions expressed in this letter are the responsibility of the authors, and do not necessarily reflect the point of view of the organizations they work for.

**Acknowledgements**

The authors would like to thank Pilar Rayón for her collaboration and comments.

Ferrán Catalá-López,\(^*\) Gloria Martín-Serrano, Miguel A. Maciá, and Dolores Montero

División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain

\(^*\) Corresponding author: 
E-mail address: ferran_catala@hotmail.com (F. Catalá-López).

Available online 16 May 2012

**REFERENCES**


**Olmesartan for the Prevention or Delay of Diabetic Nephropathy: Some Considerations. Response**

**Uso de olmesartán en la prevención o retraso de la nefropatía diabética: algunas consideraciones. Respuesta**

**To the Editor,**

We appreciate the letter from Catalá-López et al. in response to our recently published article.\(^1\) We agree that a relative risk for cardiovascular mortality that is 3 times greater in the intervention group, combining the Randomized Olmesartan And Diabetes Microalbuminuria Prevention (ROADMAP)\(^2\) and Olmesartan Reducing Incidence of Endstage renal disease in diabetic Nephropathy Trial (ORIENT)\(^3\) results, is not very promising. We find it interesting that the authors reminded us clinicians that olmesartan is authorized “exclusively” for the treatment of arterial hypertension in Spain, as the increased risk of cardiovascular death has mainly been observed in diabetic subjects, normotensive subjects for the most part, who use it to prevent diabetic nephropathy.

However, we would like to add the following considerations to the comments by Catalá-López et al. First, our study included all the articles published up to 30 April 2011 that met a series of criteria explained in detail in the original article.\(^1\) The results of the ORIENT\(^3\) study were published online (PubMed) 6 months later. Our strategy to include only indexed studies is the strategy used most frequently in systematic reviews. Second, we believe that the observations of our meta-analysis are relevant although, as Catalá-López et al. pointed out, they did not fully answer the question posed. Persistent microalbuminuria is an early sign of nephropathy in type 2 diabetics, and it is associated with the presence of macroalbuminuria and end-stage renal disease.\(^4\) In turn, it is accepted that slowing down the progression to end-stage renal disease (eg, by reducing the urinary excretion of albumin) can have a positive impact on the survival prognosis. In this regard, a lot of work has focused on angiotensin II receptor blockers and it is paradoxical that an intervention that can significantly reduce the incidence of microalbuminuria in a little over 3 years is also accompanied by unfavorable outcomes in terms of mortality. A similar finding— unfavorable— was reported in the Irbesartan Patients with Diabetes And MicroAlbuminuria (IRMA-2)\(^5\) study. Therefore, we believe that our metaanalysis was relevant in evaluating the “trends” observed in at least 2 previous studies.\(^2,3\) Finally, we also believe that the neutral effect on overall mortality we obtained (relative risk=1.04) in patients with active treatment is a cause for reflection, if not concern.

Luciano Consuegra-Sánchez,\(^a,*\) Julio Nuñez,\(^b\) Francisco Picó,\(^a\) and Juan Sanchis\(^b\)

\(^a\)Servicio de Cardiología, Hospital General Universitario de Santa Lucía, Cartagena, Murcia, Spain
\(^b\)Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain

* Corresponding author: 
E-mail address: iconsue@gmail.com (L. Consuegra-Sánchez).

Available online 11 May 2012

**REFERENCES**